Pharmaceutical Commerce

Featured Content

Pharmaceutical Commerce - December 2024

Click here to read the articles and download the PDF

Did Industry Fumble the DSCSA Deadline?

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Going Inside the Gross-to-Net Bubble and Its Nuances

A crash course on the bubble itself, including therapeutic areas most affected.

Why AI Advances in CGT Require Getting Data Right

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Pharma Pulse 7/26/24: Talent Management Strategies for Post-Milestone Growth, Dispensing Medication for Muslims & more

July 26, 2024

The latest news for pharma industry insiders.

Ardian Buys Majority Stake in Masco Group

July 25, 2024

The acquisition provides Ardian with greater insight into the life science industry.

SynaptixBio, Evotec Extend Research and Development Collaboration

July 25, 2024

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

Pharma Pulse 7/25/24: CrowdStrike Explains What Went Wrong Days After Global Tech Outage, The Future of Biosimilars & more

July 25, 2024

The latest news for pharma industry insiders.

Driving CAR-Ts for Treatment in Cancer and Immunology

July 24, 2024

A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.

Scorpius to Unveil First Mammalian cGMP Campaign at Texas Plant

July 24, 2024

The San Antonio facility will be taking this biomanufacturing initiative by the end of Q3 2024.

Pharma Pulse 7/24/24: Addressing OUD Treatment Gaps, Body Dysmorphic Disorder Most Common in Adolescent Girls & more

July 24, 2024

The latest news for pharma industry insiders.

Agilent Purchases Biovectra for $925 Million

July 23, 2024

The deal exponentially grows the CDMO’s biopharma capabilities.

Grünenthal Obtains Valinor Pharma

July 23, 2024

In a transaction valued at $250 million, the deal makes Grünenthal the new owner of Movantik, which treats OIC in adult patients with chronic non-cancer pain.

Pharma Pulse 7/23/24: The Data That Powers AI is Disappearing Fast, Stay Aware of Common High-Alert Medications & more

July 23, 2024

The latest news for pharma industry insiders.